RxDoctor Payments Data

Rachel Harsch, PA

Physician Assistant · Klamath Falls, ORNPI 1861698797

Payments from drug & device makers

$800in general payments, 2019–2025

Across 31 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$291
  • Medtronic$240
  • Novo Nordisk$194
  • Sequel Med Tech, LLC$21
  • Lilly USA, LLC$19
  • Xeris Pharmaceuticals, Inc.$19
  • plus $17 from 1 others

What the payments were for

  • Travel & lodging$202%
  • Food & beverage$78098%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$800 in reported general payments places this provider in the 80th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$23,840
Medicare patients
76
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$121,502
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog64$78,241
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$47,706
MounjaroTirzepatide29$47,195
Fiasp FlextouchInsulin Aspart (Niacinamide)16$29,166
TrulicityDulaglutide17$26,982
Tresiba Flextouch U-200Insulin Degludec11$21,448
Semglee (Yfgn) PenInsulin Glargine-Yfgn43$20,824
JardianceEmpagliflozin21$14,598
FarxigaDapagliflozin Propanediol13$12,870
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$10,722
HumalogInsulin Lispro22$8,351
Insulin Aspart FlexpenInsulin Aspart23$6,008
Insulin Aspart22$4,833
Insulin Degludec Pen (U-200)Insulin Degludec11$4,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$194$121,50295 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$19$82,52868 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Klamath Falls

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →